Related Experiment Video
Updated: Jul 13, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Long-term management of prolactinomas.
1Department of Internal Medicine, 157 MRF, University of Iowa Hospital, 200 Hawkins Drive, Iowa City, Iowa 52242, USA. janet-schlechte@uiowa.edu
The Journal of Clinical Endocrinology and Metabolism
|August 8, 2007
Summary
Prolactinomas, pituitary tumors causing infertility, require careful long-term management after treatment. Key issues include monitoring frequency, pregnancy effects, and dopamine agonist discontinuation.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Oncology
Background:
- Prolactinomas are common pituitary tumors causing gonadal dysfunction and infertility, particularly in young women.
- Dopamine agonist therapy effectively treats prolactinomas, with established mechanisms for prolactin secretion regulation.
Observation:
- Current management challenges focus on the long-term follow-up after successful prolactinoma therapy.
- Key questions involve optimal radiographic monitoring schedules and the impact of physiological states like pregnancy and menopause.
Findings:
- The safety of estrogen, including oral contraceptives, in women with a history of prolactinomas needs consideration.
- The potential for safely discontinuing dopamine agonist therapy after successful treatment is an area requiring further investigation.
Implications:
- Establishing clear guidelines for long-term prolactinoma management is crucial for patient well-being.
- Further research is needed to address specific follow-up protocols, hormonal influences, and treatment cessation strategies.
